Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of ...

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer

Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given ...
MarketScreener

Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine

Integrated clinical and translational findings provide clear direction for refining patient stratification, optimizing dosing and advancing Phase 3 development. BOSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) ...
MarketScreener

Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence

Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone 1; Benefit increased over time in invasive disease-free survival and across key secondary end ...

ITM and Lumara Bio Announce Dose-Response Analysis for ¹⁷⁷Lu-edotreotide (ITM-11) and Data Supporting Early-Stage Pipeline at EANM 2026

Dose-response analysis from Phase 3 COMPETE trial shows an association between higher absorbed doses of ¹⁷⁷Lu-edotreotide in tumors and improved ...